Abstract | IMPORTANCE OF THE FIELD: Acinetobacter baumannii has emerged as a major cause of healthcare-associated infections. It commonly presents resistance to multiple antimicrobial agents, occasionally including carbapenems and polymyxins, and hence, it is considered the paradigm of multidrug-resistant (MDR) or pandrug-resistant (PDR) bacterium. MDR A. baumannii is a rapidly emerging pathogen, especially in the intensive care setting, causing infections including bacteremia, pneumonia/ventilator-associated pneumonia (VAP), meningitis, urinary tract infection, central venous catheter-related infection, and wound infection. AREAS COVERED IN THIS REVIEW: WHAT THE READER WILL GAIN: TAKE HOME MESSAGE: Pooled data suggest that infections caused by A. baumannii, especially those with inappropriate treatment, are associated with considerable attributable mortality. The optimal treatment for A. baumannii nosocomial infections has not been established, especially for MDR strains. Therefore, well-designed clinical studies are necessary to guide clinicians on decisions regarding the best therapeutic approach for patients with MDR A. baumannii infections. In addition, new experimental studies are warranted to evaluate the activity and safety of peptides and other novel antibacterial agents for A. baumannii infections.
|
Authors | Argyris Michalopoulos, Matthew E Falagas |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 11
Issue 5
Pg. 779-88
(Apr 2010)
ISSN: 1744-7666 [Electronic] England |
PMID | 20210684
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Acinetobacter Infections
(drug therapy, microbiology)
- Acinetobacter baumannii
(drug effects, isolation & purification)
- Anti-Bacterial Agents
(adverse effects, pharmacology, therapeutic use)
- Clinical Trials as Topic
- Cross Infection
(drug therapy)
- Drug Resistance, Multiple, Bacterial
- Humans
|